高强度聚焦超声联合术前新辅助化疗治疗乳腺癌的疗效观察  

High intensity focused ultrasound combined with neoadjuvant chemotherapy for breast cancer:A therapeutic effect study

作　　者：郭晓辉[1] 周晓东[1] 任小龙[1] 陈江浩[2] 韩增辉[1] 何光彬[1] 巩箫音[1] 于铭[1] 

机构地区：[1]解放军第四军医大学西京医院超声科,西安市710032 [2]解放军第四军医大学西京医院普三科

出　　处：《临床超声医学杂志》2007年第6期333-335,共3页Journal of Clinical Ultrasound in Medicine

摘　　要：目的对乳腺癌术前做新辅助化疗的病人进行低能量的高强度聚焦超声(HIFU)治疗,探讨HIFU联合化疗药物治疗乳腺肿瘤的有效性和安全性。方法选取同期经病理确诊可手术的女性乳腺癌患者40例,分为HIFU治疗组和对照组各20例,HIFU治疗组患者术前接受化疗的同时进行一次HIFU治疗,对照组术前只接受化疗,两组患者均行乳腺癌改良根治性手术,并于治疗前后及手术前进行血常规、肝功能、肾功能和超声检查。化疗期间观察药物的不良反应。结果治疗后HIFU治疗组肿瘤原发灶的大小较对照组明显缩小(P<0.05),血流明显减少,临床分期明显降低。两组患者的不良反应比较差异无统计学意义(P>0.05)。结论HIFU联合化疗药物治疗乳腺肿瘤是安全和有效的。Objective To investigate the therapeutic efficacy of breast cancer treated with low power high intensity focused ultrasound （HIFU） in combination with neoadjuvant chemotherapy. Methods Forty operable female patients with pathologically confirmed breast cancer were divided into HIFU group and control group randomly. Preoperatively, patients in HIFU group were treated with HIFU in combination with adjuvant chemotherapy, and patients in control group were treated with adjuvant chemotherapy. All patients were accepted with improvement radical surgery. Pretreatment and post - treatment, all patients were accepted with liver function, renal function and ultrasonography examinations respectively. And medicamentous adverse reaction was observed. Results After treatment, the size of primary tumor in HIFU group decreased mere obviously than that of control group. The differences were significant （ P 〈 0. 05）. The blood tlow of primary tumor was decreased obviously and the clinical stages of most patients were cut down obviously. There was no significance of medicamentous adverse reaction in two groups （ P 〉 0.05）. Conclusion HIFU in combination with neoadjuvant chemotherapy is a safe and effective method to treat breast cancer.

关 键 词：乳腺肿瘤 高强度聚焦超声 新辅助化疗 

分 类 号：R730.5[医药卫生—肿瘤]